NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Alphina Therapeutics

Alphina Therapeutics

Private
New Haven, ConnecticutHealthcare & Life Scienceshttps://www.alphinatx.com/

Last Round

Seed Round

Mar 16, 2026

Total Funding Raised

$40M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Alphina Therapeutics is a biotechnology company developing small molecule inhibitors of NAMPT to treat a variety of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision oncologyNAMPT inhibitorcompanion diagnosticsynthetic lethalitysolid tumor therapybiotech drug discoverytargeted cancer therapypatient selection assaysmall molecule inhibitorcancer metabolismbiomarker developmentoncology pipelinepersonalized medicinedrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alphina Therapeutics Comparables

Compare Alphina Therapeutics with similar companies based on industry and business-model similarity.

Alphina Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Remedy Plan Therapeutics
87%
OncoTartis, Inc.
81%
Tessellate BIO
76%

Alphina Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundMar 16, 2026
Series ASep 1, 2021
Pre SeedDec 15, 2020

Key People

Founding team and executive leadership

Nick Galli

Chief Executive Officer

Executive Team

Stanley Choy

Chief Financial Officer

Executive Team

Alphina Therapeutics Investors

Notable investors and investment history

Alphina Therapeutics investors
InvestorRounds
Connecticut InnovationsSeries A, Pre Seed
HighCape CapitalSeries A, Pre Seed
Osage University PartnersSeries A
Canaan PartnersSeries A
Alexandria Venture InvestmentsSeries A
Alexandria Venture InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 48% month-over-month.

Alphina Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alphina Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alphina Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew Haven, Connecticut
Employee Range10
Year Founded2018
Last FundingMar 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.